Table 1 The efficacy of vaccines against SARS-CoV-2 variants of concern
From: SARS-CoV-2: phenotype, genotype, and characterization of different variants
Vaccine | Manufacturer | Type of vaccine | Vaccination status | Efficacy against Alpha | Efficacy against Beta | Efficacy against Gamma | Efficacy against Delta | Efficacy against Omicron |
|---|---|---|---|---|---|---|---|---|
BNT162b2 | Pfizer–BioNtech | RNA-based | Single dose | 29.5% [105] 70% [106] 46% [107] | 16.9% [105] 43% [108] 54.7% [109] | 61.0 | 30.7% [110] 56% [111] 64.2% [112] | 55.2% [113] |
Double dose | 89.5 [105] 85% [106], 92% [107] 95.3% [114] 94% [110] | 75.0% [105], 77% [115] 88% [108] 84.8% [109] | – | 88.0% [110] 87% [111] 75% [116] 91% [117] 53.5% [112] | 88.0% [118] | |||
mRNA-1273 | Moderna | RNA-based | Single dose | 88.1 [119], 54.5% [120] 67.0 [121] | 61.3% [119] | 61% [121] | 72% [111] 79.0% [112] | 36.7% [113] |
Double dose | 100% [119] 84.4% [120] | 96.4% [119] | – | 91% [117] 84.8% [112] 87.9% [122] | 30.4% [123] | |||
ChAdOx1 nCoV-19 | AstraZeneca | Viral vector | Single dose | 48.7% [110], 60% [124], 64% [111], 68%[125], 62% [126], 95% [127] | 75.4% [128] | 33.4% [129] | 30.7% [110] 67% [111] 46.2% [130] | – |
Double dose | 74.5% [110], 70.4% [131] | 21.9% [128] | 77.9% [129] | 67.0% [110] | 86·4% [132] | |||
BBIBP‐CorV | Sinopharm | Inactivated virus | Single dose | – | – | – | ||
Double dose | – | – | – | – | ||||
CoronaVac | Sinovac | Inactivated virus | Single dose | – | – | 49.6% [133], 12.5% [134] | – | |
Double dose | – | – | 36.8% [133], 46.8% [134] 68.1% [135] | 59.0% [135] | – | |||
NVX‐CoV‐2373 | Novavax and CEPI | Single dose | 85.6% | – | – | |||
Double dose | 60.1% [136] | – | – | – | – |